Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ISRG 
Intuitive Surgical Inc (ISRG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ISRG (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
33 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $582.1
1 Year Target Price $582.1
| 14 | Strong Buy |
| 8 | Buy |
| 10 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 83.41% | Avg. Invested days 80 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 168.90B USD | Price to earnings Ratio 65.8 | 1Y Target Price 582.1 |
Price to earnings Ratio 65.8 | 1Y Target Price 582.1 | ||
Volume (30-day avg) 33 | Beta 1.6 | 52 Weeks Range 425.00 - 616.00 | Updated Date 08/28/2025 |
52 Weeks Range 425.00 - 616.00 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 7.16 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 28.51% | Operating Margin (TTM) 30.47% |
Management Effectiveness
Return on Assets (TTM) 9.02% | Return on Equity (TTM) 16.04% |
Valuation
Trailing PE 65.8 | Forward PE 59.52 | Enterprise Value 163569705801 | Price to Sales(TTM) 18.47 |
Enterprise Value 163569705801 | Price to Sales(TTM) 18.47 | ||
Enterprise Value to Revenue 17.89 | Enterprise Value to EBITDA 51.59 | Shares Outstanding 358476992 | Shares Floating 356311308 |
Shares Outstanding 358476992 | Shares Floating 356311308 | ||
Percent Insiders 0.53 | Percent Institutions 88.99 |
Upturn AI SWOT
Intuitive Surgical Inc
Company Overview
History and Background
Intuitive Surgical Inc. was founded in 1995. Initially named Intuitive Devices, Inc., it developed the da Vinci Surgical System, a robotic surgical system, which received FDA approval in 2000. This marked a significant shift toward minimally invasive surgery.
Core Business Areas
- Surgical Systems: Designs, manufactures, and markets the da Vinci surgical systems and related instruments and accessories. These systems allow surgeons to perform minimally invasive procedures.
- Instruments and Accessories: Offers a range of instruments and accessories used with the da Vinci system. These are critical for performing different surgical procedures.
- Services: Provides services, including installation, training, maintenance, and repair services for da Vinci systems.
Leadership and Structure
The CEO is Gary S. Guthart. The company has a typical corporate structure with departments for research and development, manufacturing, sales, marketing, and operations. It operates globally with regional headquarters and sales offices.
Top Products and Market Share
Key Offerings
- da Vinci Surgical System: A robotic surgical system that allows surgeons to perform minimally invasive procedures with enhanced precision, dexterity, and control. Intuitive Surgical dominates the market for surgical robots. While specific market share varies, they hold a significant portion of the robotic surgery market. Competitors include Stryker (STRK), Medtronic (MDT), and Johnson & Johnson (JNJ) (through Ethicon).
- Instruments and Accessories: A range of instruments and accessories used with the da Vinci system, including endoscopes, staplers, and energy devices. Revenue is derived through continued sales of these essential disposables. Competitors include Stryker (STRK), Medtronic (MDT), and Johnson & Johnson (JNJ).
Market Dynamics
Industry Overview
The surgical robotics market is experiencing significant growth, driven by the increasing demand for minimally invasive procedures, technological advancements, and an aging population. The trend toward robotic-assisted surgery is driven by reduced recovery times, smaller incisions, and improved surgical outcomes.
Positioning
Intuitive Surgical is the market leader in surgical robotics. Its competitive advantages include its established brand, extensive installed base of da Vinci systems, strong intellectual property portfolio, and continuous innovation in surgical technology.
Total Addressable Market (TAM)
The TAM for robotic-assisted surgery is estimated to be tens of billions of dollars and is expected to continue growing. Intuitive Surgical is well-positioned to capture a significant share of this market.
Upturn SWOT Analysis
Strengths
- Market leader in surgical robotics
- Strong brand recognition
- Large installed base of da Vinci systems
- Extensive intellectual property portfolio
- Continuous innovation
Weaknesses
- High cost of da Vinci systems
- Dependence on disposable instruments and accessories
- Training requirements for surgeons
- Geographic concentration of revenue
Opportunities
- Expansion into new surgical specialties
- Growth in emerging markets
- Development of new robotic technologies
- Partnerships with hospitals and healthcare providers
Threats
- Increasing competition from other surgical robotics companies
- Regulatory challenges and scrutiny
- Economic downturns affecting hospital capital spending
- Patent expirations
Competitors and Market Share
Key Competitors
- STRK
- MDT
- JNJ
Competitive Landscape
Intuitive Surgical maintains a significant competitive advantage due to its early mover advantage, extensive installed base, and strong brand recognition. However, competitors are investing heavily in surgical robotics, and the competitive landscape is becoming more intense.
Major Acquisitions
Schu00f6lly Fiberoptic GmbH
- Year: 2019
- Acquisition Price (USD millions): 190
- Strategic Rationale: Expanded visualization capabilities and enhanced supply chain control.
Growth Trajectory and Initiatives
Historical Growth: Intuitive Surgical has experienced significant revenue growth over the past decade, driven by the increasing adoption of robotic-assisted surgery. The growth has been somewhat hampered by COVID as elective surgeries were affected.
Future Projections: Analysts project continued revenue growth for Intuitive Surgical, fueled by new product launches, expansion into new markets, and increasing demand for minimally invasive surgery. Growth is expected to be in the double digits.
Recent Initiatives: Recent initiatives include the development of new da Vinci systems, the expansion of its instrument and accessory portfolio, and strategic acquisitions to expand its product offerings and market reach.
Summary
Intuitive Surgical is a strong company with a dominant position in the growing surgical robotics market. Its established brand, large installed base, and continuous innovation contribute to its success. However, it needs to be mindful of increasing competition, regulatory scrutiny, and the high cost of its systems, potentially affecting future growth and market share.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Analyst Reports
- Company Investor Relations
- Market Research Reports
- Earnings Transcripts
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor. Market share estimates are approximate and based on available data and industry analysis.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Intuitive Surgical Inc
Exchange NASDAQ | Headquaters Sunnyvale, CA, United States | ||
IPO Launch date 2000-06-13 | CEO & Director Mr. David J. Rosa | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 15638 | Website https://www.intuitive.com |
Full time employees 15638 | Website https://www.intuitive.com | ||
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.